JP2021506941A5 - - Google Patents

Download PDF

Info

Publication number
JP2021506941A5
JP2021506941A5 JP2020534861A JP2020534861A JP2021506941A5 JP 2021506941 A5 JP2021506941 A5 JP 2021506941A5 JP 2020534861 A JP2020534861 A JP 2020534861A JP 2020534861 A JP2020534861 A JP 2020534861A JP 2021506941 A5 JP2021506941 A5 JP 2021506941A5
Authority
JP
Japan
Prior art keywords
alkyl
pyrrolo
piperidinyl
pyrrolidinyl
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020534861A
Other languages
English (en)
Japanese (ja)
Other versions
JP7382938B2 (ja
JP2021506941A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/066108 external-priority patent/WO2019126083A1/en
Publication of JP2021506941A publication Critical patent/JP2021506941A/ja
Publication of JP2021506941A5 publication Critical patent/JP2021506941A5/ja
Application granted granted Critical
Publication of JP7382938B2 publication Critical patent/JP7382938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020534861A 2017-12-20 2018-12-18 ジアザインドール化合物 Active JP7382938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607941P 2017-12-20 2017-12-20
US62/607,941 2017-12-20
PCT/US2018/066108 WO2019126083A1 (en) 2017-12-20 2018-12-18 Diazaindole compounds

Publications (3)

Publication Number Publication Date
JP2021506941A JP2021506941A (ja) 2021-02-22
JP2021506941A5 true JP2021506941A5 (pt-PT) 2022-01-06
JP7382938B2 JP7382938B2 (ja) 2023-11-17

Family

ID=65003573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534861A Active JP7382938B2 (ja) 2017-12-20 2018-12-18 ジアザインドール化合物

Country Status (13)

Country Link
US (1) US11299501B2 (pt-PT)
EP (1) EP3728264B1 (pt-PT)
JP (1) JP7382938B2 (pt-PT)
CN (1) CN111511744B (pt-PT)
AU (1) AU2018390544A1 (pt-PT)
BR (1) BR112020012002A2 (pt-PT)
CA (1) CA3085937A1 (pt-PT)
EA (1) EA202091530A1 (pt-PT)
ES (1) ES2904773T3 (pt-PT)
IL (1) IL275505A (pt-PT)
MX (1) MX2020006014A (pt-PT)
SG (1) SG11202005733QA (pt-PT)
WO (1) WO2019126083A1 (pt-PT)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291707B2 (ja) 2017-12-20 2023-06-15 ブリストル-マイヤーズ スクイブ カンパニー アリールおよびヘテロアリール置換されたインドール化合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3086431A1 (en) * 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
EP3807270B1 (en) 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
CN112638908A (zh) 2018-09-04 2021-04-09 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的苯并噻唑类化合物
CN112654618A (zh) 2018-09-06 2021-04-13 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的新型环脒化合物
WO2022166920A1 (zh) * 2021-02-08 2022-08-11 杭州中美华东制药有限公司 一种吡咯并哒嗪类化合物及其制备方法和用途
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
IL314945A (en) * 2022-02-18 2024-10-01 Bristol Myers Squibb Co Alternative imidazopyridinyl compounds are useful as TLR9 inhibitors
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6867200B1 (en) 1998-12-18 2005-03-15 Axys Pharmaceuticals, Inc. (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
MXPA02003887A (es) 1999-10-19 2002-09-30 Merck & Co Inc Inhibidores de tirosina cinasa.
MXPA04006614A (es) 2002-01-07 2004-10-04 Eisai Co Ltd Deazapurinas y usos de las mismas.
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター(tlr)アンタゴニスト
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス, インコーポレイテッド 疾患および障害のための化合物
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
ATE495743T1 (de) 2006-12-01 2011-02-15 Galapagos Nv Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
JP5486602B2 (ja) 2008-09-26 2014-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾオキサゾール化合物および使用方法
EP2340243B1 (en) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
WO2011009015A1 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
WO2011036130A1 (en) 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
JP2013166700A (ja) * 2010-06-02 2013-08-29 Dainippon Sumitomo Pharma Co Ltd 新規4,5−縮環ピリミジン誘導体
US9241991B2 (en) 2010-10-21 2016-01-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritus and related skin conditions
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
PT2663555T (pt) 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
BR112013030894A2 (pt) 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
JP6463631B2 (ja) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Gpr−119のモジュレータとしての新規化合物
CN103874702B (zh) 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
JP2013075834A (ja) * 2011-09-29 2013-04-25 Kowa Co Tlr9阻害活性を有するピラゾロピリミジン−7−アミン誘導体
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
US20130158040A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. Diazaindole inhibitors of crac
CN104302628B (zh) 2012-05-18 2017-06-23 大日本住友制药株式会社 羧酸化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CN106414432B (zh) 2013-10-14 2019-06-14 卫材R&D管理有限公司 选择性取代的喹啉化合物
JP2016540013A (ja) 2013-12-13 2016-12-22 武田薬品工業株式会社 Tlr阻害剤としてのピロロ[3,2−c]ピリジン誘導体
CN110759916B (zh) 2014-08-15 2021-02-19 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
JP2017525711A (ja) 2014-08-22 2017-09-07 ジャナス バイオセラピューティクス,インク. 新規なn2,n4,n7,6−四置換プテリジン−2,4,7−トリアミンおよび2,4,6,7−四置換プテリジン化合物ならびにその合成方法および使用
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3490983B1 (en) 2016-07-30 2021-02-17 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル-マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
AR113959A1 (es) 2017-12-18 2020-07-01 Bristol Myers Squibb Co Compuestos de 4-azaindol
EA202091508A1 (ru) 2017-12-19 2020-09-14 Бристол-Маерс Сквибб Компани 6-азаиндольные соединения

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291707B2 (ja) 2017-12-20 2023-06-15 ブリストル-マイヤーズ スクイブ カンパニー アリールおよびヘテロアリール置換されたインドール化合物

Similar Documents

Publication Publication Date Title
JP2021506941A5 (pt-PT)
JP2021507912A5 (pt-PT)
AU2019203444B2 (en) Bicyclic lactams and methods of use thereof
JP7382938B2 (ja) ジアザインドール化合物
JP2021503004A5 (pt-PT)
TWI741423B (zh) 雜芳類衍生物調節劑、其製備方法和應用
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
JP2021506858A5 (pt-PT)
CN114245794B (zh) 用于治疗亨廷顿氏病的化合物
AU2010249380B2 (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
AU2019216728A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
KR101800749B1 (ko) 신규한 헤테로사이클 유도체 및 그의 용도
JP2020529436A5 (pt-PT)
JP2015537010A5 (pt-PT)
RU2014102962A (ru) Новые соединения-ингибиторы фосфодиэстеразы типа 10а
HRP20120105T1 (hr) Aminoheterociklički spojevi
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
AU2006283935A1 (en) Fused pyrazole as p38 MAP kinase inhibitors
JP2017518326A5 (pt-PT)
JP2014528482A5 (pt-PT)
JP2021506816A5 (pt-PT)
JPWO2019191229A5 (pt-PT)
JP2021504380A5 (pt-PT)